Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Journal
Journal of the American Academy of Dermatology
Journal Volume
86
Journal Issue
4
Pages
827
Date Issued
2022
Author(s)
Blauvelt, Andrew
Langley, Richard G
Miller, Megan
Shen, Yaung-Kaung
You, Yin
Yang, Ya-Wen
Papp, Kim A
Puig, Luis
Abstract
Guselkumab effectively treats moderate-to-severe psoriasis.
Subjects
adverse events; biologics; guselkumab; infections; malignancy; psoriasis; safety
SDGs
Publisher
MOSBY-ELSEVIER
Type
journal article